Arrhythmias & electrophysiology
Nonalcoholic fatty liver disease is associated with ventricular arrhythmias and major cardiovascular events in patients with implantable cardioverter-defibrillators
Authors' conclusion
In our retrospective cohort, NAFLD is significantly associated with VAs and major cardiovascular events in patients with ICDs.
Study context
- Population
- Patients at high risk of SCD who received implantable cardioverter-defibrillators (ICDs)
- Participants
- 921 patients
- Exposure
- Nonalcoholic fatty liver disease (NAFLD) vs no NAFLD
- NAFLDn = 223
- Outcome
- Ventricular arrhythmias (VAs) (sustained VT and VF documented by the device)
- Follow-up
- Mean 34.8 months
Main finding
As reported in the abstract
VAs
NAFLD vs No NAFLDHazard ratio (95% CI)P value
Kaplan-Meier
3.90(2.87–5.29)
log-rank P < .0001Adjusted Cox regression
3.84(2.87–5.12)
P < 0.001Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Cardiac mortality, heart transplantation or rehospitalization for HFNAFLDvs No NAFLDKaplan-Meier | 2.04 (1.72–2.94) | log-rank P < .0001 | |
| Cardiac mortality, heart transplantation or rehospitalization for HFNAFLDvs No NAFLDAdjusted Cox regression | 2.26 (1.55–3.28) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
- Cardiac mortality, heart transplantation or rehospitalization for HF: 171 (18.6%) patients reached secondary end points overall
Prevalence of NAFLD in patients with ICDs
- NAFLD prevalence (223/921)
- 24.2%
Original publication
Nonalcoholic fatty liver disease is associated with ventricular arrhythmias and major cardiovascular events in patients with implantable cardioverter-defibrillators. Heart Rhythm. Published 28 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →